𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase II study of subcutaneous recombinant human lnterleukjn-4 in metastatic renal cell carcinoma

✍ Scribed by Walter M. Stadler; Mary Ellen Rybak; Nicholas J. Vogelzang

Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
462 KB
Volume
76
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II trial of subcutaneously adminis
Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma
✍ Edward Wos; Thomas Olencki; Laurie Tuason; G. Thomas Budd; David Peereboom; Kate πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 465 KB πŸ‘ 2 views

## BACKGROUND. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine that is involved in the differentiation and proliferation of various hematopoietic precursors. It also has been reported to enhance the antitumor activity of various mature effector cells. Previous reports have

A phase II study of constant-infusion fl
A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma
✍ Mary J. Wilkinson; John W. Frye; Eric J. Small; Alan P. Venook; Peter R. Carroll πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 347 KB πŸ‘ 2 views

Background. Twenty-nine patients with metastatic renal cell carcinoma (RCC) were treated with constantinfusion floxuridine (FUdR, Roche Laboratories, Nut-Methods. The initial dosage was 0.075 mg/kg/day for 14 days every 28 days and was increased or decreased by 0.025-mg/kg/day increments at each sub